Soligenix’s Thermostable Filovirus Vaccine Program Has Potential For Global Impact
Company’s ThermoVax® platform has demonstrated protection against potentially lethal Ebola viruses
Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharma company focused on developing and commercializing products to treat rare diseases continues work on its vital vaccine development program as a new outbreak of Sudan ebolavirus is declared in Uganda.
While there is a vaccine for Zaire ebolavirus, there is no vaccine or therapeutic for Sudan ebolavirus. Ebola viral diseases are severe and often fatal illnesses with no approved post-exposure therapies, highlighting the critical need for effective vaccines.
A heat stable vaccine in a single vial format, such as Soligenix’s ThermoVax® candidates, would significantly enhance future public health responses to outbreaks.
What you need to know
- Soligenix’s vaccine provides 100% protection in non-human primates against Sudan ebolavirus
- The company’s vaccines have been shown to maintain full potency and thermostability (104 degrees Fahrenheit for 12 weeks) demonstrating the broad applicability of its heat stable vaccine platform;
- Soligenix’s work has demonstrated the feasibility of rapid and efficient manufacturing, as well as the ability to thermostabilize multiple antigens that can be stored at temperatures exceeding 100 degrees Fahrenheit.
A pre-IND meeting with the FDA to discuss the clinical development of this vaccine candidate is expected to be initiated within the next 12 months.